SEC Company Response from Aptose Biosciences Inc. (CIK 0000882361) (APTOF) — May 23, 2007

Aptose Biosciences Inc. (CIK 0000882361)
Date: May 23, 2007 · CIK: 0000882361 · Accession: 0001279569-07-000755

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-32001

Date

March 30, 2007

Author

/s/

Form

CORRESP

Company

Aptose Biosciences Inc. (CIK 0000882361)

Letter

Securities and Exchange Commission F Street, NE Washington, D.C. Filed: EDGAR/CORRESP

Re: Comment Letter, dated March 30, 2007 related to

Dear Sirs and Mesdames,

Form 20-F for fiscal year ended May 31, 2006 (the “Comment Letter”) File No. 001-32001

Lorus Therapeutics Inc. hereby notifies the Securities and Exchange Commission that it currently expects to provide responses to the comments contained in the Comment Letter on or before June 15, 2007.

Sincerely,
/s/
Mark Preston

Show Raw Text

CORRESP
1
filename1.htm

      Correspondence with the SEC

    May
      23, 2007

    Securities
      and Exchange Commission

    100
      F Street, NE

    Washington,
      D.C.

    20549

    Filed:
      EDGAR/CORRESP

    Dear
      Sirs and Mesdames,

    Re:     Comment
      Letter, dated March 30, 2007 related to

    Form
      20-F for fiscal year ended May 31, 2006 (the “Comment Letter”) File No.
      001-32001

    Lorus
      Therapeutics Inc. hereby notifies the Securities and Exchange Commission that
      it
      currently expects to provide responses to the comments contained in the Comment
      Letter on or before June 15, 2007.

    Sincerely,

    /s/
      Mark Preston

    Mark
      Preston,

    Acting
      Controller

              LORUS
                THERAPEUTICS INC.

              2
                Meridian Road

              Toronto,
                Ontario

              M9W
                4Z7

              T:
                416.798.1200

              F:
                416.798.2200

              www.lorusthera.com

              info@lorusthera.com

SecProbe.io